Clinigen Group (OTCMKTS:CLIGF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of CLIGF traded down $0.53 during mid-day trading on Friday, reaching $10.17. 5,250 shares of the company were exchanged, compared to its average volume of 313. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.95 and a quick ratio of 0.80. Clinigen Group has a 52 week low of $10.17 and a 52 week high of $10.70. The business has a 50 day simple moving average of $11.63 and a two-hundred day simple moving average of $12.32.

Recommended Story: High-Yield Dividend Stocks

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.